Alnylam Pharmaceuticals, Inc., the global leader in RNA interference (RNAi) therapeutics, has announced the launch of its new five-year corporate strategy, “Alnylam 2030,” outlining an ambitious roadmap to scale operations, strengthen leadership in transthyretin (ATTR) amyloidosis, advance a diversified pipeline…
argenx SE a global immunology company focused on developing innovative therapies for patients with severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VYVGART® (intravenous…
Inside a laboratory in Cambridge, Massachusetts, Shawn Walker, Global Head of Synthetic Chemistry, Manufacturing and Controls (CMC) Development, gestures toward one of his most distinctive team members. Known as “Solutron,” the system is a sophisticated network of robotic arms, joints,…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has released a comprehensive set of business and pipeline updates ahead of its scheduled investor meetings in January, underscoring strong commercial momentum and continued advancement across its research and development portfolio. These updates will be…
Pfizer Inc has announced encouraging new clinical data from Cohort 3 of the pivotal Phase 3 BREAKWATER trial, reinforcing the potential of its targeted therapy BRAFTOVI® (encorafenib) to improve outcomes for patients with previously untreated metastatic colorectal cancer (mCRC) harboring…
Thermo Fisher Scientific Inc. a global leader in serving science, has announced a strategic collaboration with NVIDIA aimed at advancing the use of artificial intelligence (AI) across scientific instrumentation and laboratory operations. This partnership brings together Thermo Fisher’s extensive portfolio…
FDA Accepts Merck’s New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor Merck, a global leader in science and technology, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pimicotinib,…
Longer-Term OrigAMI-1 Results Highlight Durable Activity of Amivantamab-Based Regimens in Metastatic Colorectal Cancer Johnson & Johnson has announced encouraging longer-term follow-up results from the Phase 1b/2 OrigAMI-1 clinical study evaluating amivantamab-vmjw, an investigational bispecific antibody targeting both epidermal growth factor…
NVIDIA and Eli Lilly Launch Pioneering AI Co-Innovation Lab to Redefine Drug Discovery NVIDIA and Eli Lilly and Company have announced the creation of a groundbreaking AI co-innovation lab designed to apply advanced artificial intelligence technologies to some of the…
SAGA Diagnostics Highlights Clinical Validity of Pathlight™ MRD in TNBC During SABCS Presentations SAGA Diagnostics Highlights Clinical Validity of Pathlight™ MRD in TNBC During SABCS Presentations. SAGA Diagnostics®, a leader in blood-based cancer detection and precision oncology, continued to advance…